The US Justice Department has revealed that American drugs company Johnson & Johnson has agreed to pay over $2.2 billion as part of the settlement of allegations over its marketing techniques.
The company had been accused of paying incentives to doctors and pharmacies in order to promote three of its medicines, including anti-psychotic drugs Risperdal and Invega and heart drug Natrecor.
The company has also been accused of promoting drugs for uses not officially allowed.
"They lined their pockets at the expense of the American taxpayers, patients and the private insurance industry. They drove up costs for everyone in the healthcare system and negatively impacted the long term solvency of the central healthcare programmes like Medicare", US Attorney General Eric Holder said.